Donald Max Engelman (born 1941) is Higgins Professor of Biochemistry at Yale University. He is a member of the National Academy of Sciences (1997), fellow of the American Academy of Arts and Sciences,[3] a fellow of the National Institutes of Health, and has been a Guggenheim fellow.[4] He served as the editor of the Annual Review of Biophysics and Biophysical Chemistry (1984–1993).[5]
Donald Max Engelman | |
|---|---|
| Alma mater | |
| Awards | |
| Website | medicine |
| Born | 1941 (age 82–83) |
| Education | Reed College, Yale University |
| Awards | Guggenheim fellow |
| Scientific career | |
| Fields | Cancer drugs and treatments |
| Institutions | Yale University |
| Thesis | Solubilization and Aggregation Properties of Membrane Components from Mycoplasma laidlawii (1968) |
| Doctoral students | Mark A. Lemmon[1][2] |
He is a director of the Stryker Corporation.[6] He is involved in the creation of new cancer drugs and treatments.[7] For example, Engelman is involved in research to use peptides to aid in destroying tumors.[8]
Administration, advising, and consulting
editEngelman has served as Director of Biological Sciences at Yale, an advisor to the Brookhaven National Laboratory, and a consultant to the Los Alamos National Laboratory.[9] He also served as Acting Dean of Yale College in 1991.[10]
Education
editEngelman is a graduate (and trustee[11]) of Reed College receiving his degree in physics. He then earned his Ph.D. in molecular biophysics at Yale University in 1969.[12][13]
Engelman Lab
editEngelman directs the Engelman Laboratory at Yale focused on the biophysics of biological membranes. His group is best known for elucidating the mechanism of pH Low Insertion Peptide (pHLIP) to form trans-membrane helices.[13][14]
Patents
editEngelman holds six United States patents for his discoveries.[15]
References
edit- ^ Lemmon, Mark A.; Flanagan, John M.; Treutlein, Herbert R.; Zhang, Jian; Engelman, Donald M. (1992). "Sequence specificity in the dimerization of transmembrane .alpha.-helixes". Biochemistry. 31 (51): 12719–12725. doi:10.1021/bi00166a002. PMID 1463743.
- ^ Lemmon, Mark Andrew (1993). Specific interactions between transmembrane alpha-helices: Their role in the oligomerization of integral membrane proteins (PhD thesis). Yale University. ProQuest 304065037. (subscription required)
- ^ "REED COLLEGE AMERICAN ACADEMY OF ARTS AND SCIENCES AWARDS". reed.edu. Retrieved 2024-09-02.
- ^ "All Fellows - John Simon Guggenheim Memorial Foundation". Gf.org. Archived from the original on 2011-06-28. Retrieved 2011-07-06.
- ^ "Engelman and de la Huerga join the board of trustees". Reed Magazine. August 2000. Retrieved 17 December 2020.
- ^ "Donald M. Engelman Profile - Forbes.com". People.forbes.com. Retrieved 2011-07-06.[dead link]
- ^ redOrbit (27 October 2009). "URI Research Couple's Method Targets Cancerous Tumors - Redorbit". Redorbit.
- ^ "Home".
- ^ "Reed Magazine: News of the College".
- ^ "A Yale College Dean Is Named". The New York Times. 1991-10-15.
- ^ "List of Public Companies Worldwide, Letter - Businessweek - Businessweek". Businessweek.com.[dead link]
- ^ "The Engelman Lab - Donald M. Engelman". Yale.edu. Archived from the original on 2012-01-10. Retrieved 2011-07-06.
- ^ a b Roy, Yash; am, Giri Viswanathan 12:37 (2 February 2022). "Two Yale faculty members elected as fellows of the American Association for the Advancement of Science". Yale Daily News.
{{cite news}}: CS1 maint: numeric names: authors list (link) - ^ Reshetnyak, Yana K.; Andreev, Oleg A.; Segala, Michael; Markin, Vladislav S.; Engelman, Donald M. (7 October 2008). "Energetics of peptide (pHLIP) binding to and folding across a lipid bilayer membrane". Proceedings of the National Academy of Sciences. 105 (40): 15340–15345. Bibcode:2008PNAS..10515340R. doi:10.1073/pnas.0804746105. PMC 2556629. PMID 18829441.
- ^ "Donald M Engelman, Page 1".